Cited by 22Caveolin-1 and cellular processesAngiogenesis and VEGF in CancerFlavonoids in Medical Research

The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.

The critical roles of caveolin-1 in lung diseases

Open access
Fan, Jiarun, Zheng, Siping, Wang, Maoping, Yuan, Xiaoliang·2024·Frontiers in Pharmacology

Abstract

Caveolin-1 (Cav-1), a structural and functional component in the caveolae, plays a critical role in transcytosis, endocytosis, and signal transduction. Cav-1 has been implicated in the mediation of cellular processes by interacting with a variety of signaling molecules. Cav-1 is widely expressed in the endothelial cells, smooth muscle cells, and fibroblasts in the various organs, including the lungs. The Cav-1-mediated internalization and regulation of signaling molecules participate in the physiological and pathological processes. Particularly, the MAPK, NF-κB, TGFβ/Smad, and eNOS/NO signaling pathways have been involved in the regulatory effects of Cav-1 in lung diseases. The important effects of Cav-1 on the lungs indicate that Cav-1 can be a potential target for the treatment of lung diseases. A Cav-1 scaffolding domain peptide CSP7 targeting Cav-1 has been developed. In this article, we mainly discuss the structure of Cav-1 and its critical roles in lung diseases, such as pneumonia, acute lung injury (ALI), asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, pulmonary fibrosis, and lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2024.1417834

Cites

218 of 218 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 The protein structure of Cav-1. The Cav-1 protein has three regions: NTD (residues 1–101), membrane spanning region (residues 102–134), and CTD (residues 135–178). CSD (residue 82–101) is the region for Cav-1 to interact with various signaling molecules. The residues Tyr14 and Ser80 are the two phosphorylation sites. The residues Cys133, Cys143, and Cys156 can be palmitoylated.
FIGURE 1 The protein structure of Cav-1. The Cav-1 protein has three regions: NTD (residues 1–101), membrane spanning region (residues 102–134), and CTD (residues 135–178). CSD (residue 82–101) is the region for Cav-1 to interact with various signaling molecules. The residues Tyr14 and Ser80 are the two phosphorylation sites. The residues Cys133, Cys143, and Cys156 can be palmitoylated.CC BY · PubMed Central
FIGURE 2 Structure and functions of Cav-1. (A) The localization of Cav-1 in caveolae. The primary actions of Cav-1 include endocytosis, lipid regulation, and signaling transduction. (B) The monomer of Cav-1 and the Cav-1 scaffolding domain (CSD) were shown. Cav-1 can modulate various pathways, such as MAPK, NF-κB, TGFβ/Smad, and eNOS/NO signaling, via binding to the CSD.
FIGURE 2 Structure and functions of Cav-1. (A) The localization of Cav-1 in caveolae. The primary actions of Cav-1 include endocytosis, lipid regulation, and signaling transduction. (B) The monomer of Cav-1 and the Cav-1 scaffolding domain (CSD) were shown. Cav-1 can modulate various pathways, such as MAPK, NF-κB, TGFβ/Smad, and eNOS/NO signaling, via binding to the CSD.CC BY · PubMed Central
FIGURE 3 The biological functions of Cav-1 in protection against lung diseases. Cav-1 exhibits protective effects against pneumonia, ALI, asthma, COPD, pulmonary hypertension, pulmonary fibrosis, and lung cancers. The potential mechanisms might be associated with the inhibitory activity of Cav-1 against MAPK, NF-κB, STATs, eNOS, ERK1/2, TGFβ1, Th17/Treg disruption, NOXs, AKT, Wnt/β-catenin, and ROS.
FIGURE 3 The biological functions of Cav-1 in protection against lung diseases. Cav-1 exhibits protective effects against pneumonia, ALI, asthma, COPD, pulmonary hypertension, pulmonary fibrosis, and lung cancers. The potential mechanisms might be associated with the inhibitory activity of Cav-1 against MAPK, NF-κB, STATs, eNOS, ERK1/2, TGFβ1, Th17/Treg disruption, NOXs, AKT, Wnt/β-catenin, and ROS.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 218 references

Cited by

Sorted by citations

See all 22

Metadata

Authors
Fan, J., Zheng, S., Wang, M., & Yuan, X.
Affiliations
First Affiliated Hospital of Gannan Medical University (CN)
Corresponding author
Yuan, Xiaoliang
Venue
Frontiers in Pharmacology
Published
2024-09-24
Volume
15
Pages
1417834-1417834
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4402753012
Cited by
21
References
218
Citations by year
2026: 14 · 2025: 6 · 2024: 1
FWCI
1.11
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords
caveolin-1, caveolae, lung disease, MAPK signaling, NF-κB signaling, TGF-β/Smad signaling, pneumonia, acute lung injury, asthma, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary fibrosis, lung cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review